ST香雪：公司重视TAEST16001的临床价值与市场潜力 正全力推进确证性临床试验筹备阶段的工作

Group 1 - The company emphasizes the clinical value and market potential of TAEST16001 and is actively advancing the preparatory phase for confirmatory clinical trials [1] - The company has previously disclosed progress in the new drug development stage and will continue to announce updates based on clinical situations in accordance with information disclosure rules [1] - Investors have raised concerns regarding the lack of transparency about the enrollment status of the confirmatory clinical trial, questioning why the company has not provided clear updates [3] Group 2 - The company has received recognition from the CDE for the confirmatory clinical trial plan for TAEST16001, but has not publicly disclosed whether the first patient has been enrolled [3] - Investors are demanding clarity on the enrollment status, indicating that this is a core asset and they have the right to be informed [3]